SONIA trial - no published.

Important study that I was honored to discuss #ASCO23.

❓Question remains WHO are the right patients to delay CDK4/6i
➕Manuscript has more info on post-2nd line therapy - which was similar (80+% chemo) in both arms.

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.

Provocative data from #SONIA (initially presented at #ASCO23) suggest no difference in using #CDK4/6 inhibitor early vs. deferred in ER+ #mBC; however, #CDK4/6 will likely continue moving to #adjuvant tx so this question might become less relevant www.nature.com/articles/s41...

It was great to see so many friends at #ASCO23 yesterday! @RujulParikh @shao_yusra @HBatraSharmaMD

Early career trainee networking at #ASCO23 #ScrippsHEMONCFellowship